Loading clinical trials...
Loading clinical trials...
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia
Conditions
Interventions
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
Defactinib
Locations
5
Australia
Prince of Wales Hospital
Sydney, New South Wales, Australia
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Concord Repatriation and General Hospital
Sydney, New South Wales, Australia
Nepean Hospital
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Start Date
December 14, 2022
Primary Completion Date
August 30, 2026
Completion Date
December 30, 2027
Last Updated
March 18, 2026
NCT05564390
NCT07320235
NCT06782542
NCT06284486
NCT07523555
NCT07295951
Lead Sponsor
Clinical Hub for Interventional Research (CHOIR)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions